Work

Abstract CT036: Bioavailability of MK-3475A (pembrolizumab with berahyaluronidase alfa; “subcutaneous pembrolizumab”) in participants with advanced or metastatic solid tumors

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-ct036

Authors: Oscar Reig Torras, Graham Cohen, Byoung Chul Cho, Carlos Rojas, Cathryn Walton, Laura Medina, Richard Khanyile, Zsuzsanna Papai, Mallika Lala, Gina Song, Omobolaji Akala, Corlia Coetzee

Institutions: Hospital Clínic de Barcelona, Life Groenkloof Hospital, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Hospital Clínico Universitario Virgen de la Victoria, Steve Biko Hospital, Merck & Co., Inc., Rahway, NJ, USA (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409822403

Cites:

Cited by: 3

Related to: 10